Arctic Bioscience - Clinical Trial Application for HRO350 Phase IIb approved in the UK

12 Jan 2023 18:21 CET

Company Name

ARCTIC BIOSCIENCE AS

ISIN

NO0010859580

Market

Euronext Growth

Symbol

ABS

Reference is being made to the stock exchange release from October 10th 2022,
where Arctic Bioscience announced that Clinical Trial Application (CTA) for a
Phase IIb clinical trial in mild-to-moderate psoriasis with the investigational
medicinal product (IMP) HRO350 was submitted to medicinal authorities.

Arctic Bioscience is pleased to announce that the CTA has been approved in the
UK. Today, January 12th 2023, the Health Research Authority (HRA) gave its
approval for clinical trial start in the UK "A Phase IIb, multicenter,
randomized, double-blind, placebo-controlled, dose-finding, efficacy and safety
study of HRO350 in patients with mild-to-moderate psoriasis" (the 'HeROPA'
study). The CTA was simultaneously also approved by The United Kingdom (UK)
Medicines & Healthcare products Regulatory Agency (MHRA), the UK Research Ethics
Committee (REC). This is a major regulatory milestone in the drug development
program for HRO350.

Arctic Bioscience is currently in the process of activating the clinical trial
sites in the UK, and first patient inclusion is expected later this month.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Christer L. Valderhaug

CEO of Arctic Bioscience AS

Mobile: +47 920 84 601

Email: christer@arctic-bioscience.com

Jone R. Slinning

CFO of Arctic Bioscience AS

Mobile: +47 948 75 469

Email: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a team of highly competent people with experience in
developing marine oils and experience from global pharmaceutical companies.


Source

Arctic Bioscience AS

Provider

Oslo Børs Newspoint